QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:ORMP

Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

$2.16
-0.06 (-2.70%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.13
$2.24
50-Day Range
$1.93
$2.54
52-Week Range
$1.81
$13.73
Volume
629,846 shs
Average Volume
1.99 million shs
Market Capitalization
$85.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Oramed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
779.6% Upside
$19.00 Price Target
Short Interest
Healthy
2.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Oramed Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$293,240 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

593rd out of 986 stocks

Pharmaceutical Preparations Industry

287th out of 477 stocks


ORMP stock logo

About Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
H.C. Wainwright Reaffirms Their Hold Rating on Oramed Pharm (ORMP)
Oramed Pharmaceuticals Inc. (ORMP.TA)
How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Oramed Pharmaceuticals Issues Shareholder Update
Why Oramed Pharmaceuticals Stock Is Crashing Today
Oramed’s oral insulin pill fails; stock is down 72%
ORMP: Data from NASH Phase 2 Study – Positive Takeaways
See More Headlines
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Company Calendar

Last Earnings
1/10/2022
Today
3/22/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORMP
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+779.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-36,560,000.00
Net Margins
-1,353.35%
Pretax Margin
-1,393.42%

Debt

Sales & Book Value

Annual Sales
$2.70 million
Book Value
$3.86 per share

Miscellaneous

Free Float
37,039,000
Market Cap
$85.92 million
Optionable
Optionable
Beta
1.83

Key Executives

  • Nadav KidronNadav Kidron
    President, Chief Executive Officer & Director
  • Joshua Hexter
    Chief Operating & Business Officer
  • Miriam Kidron
    Director & Chief Scientific Officer
  • Michael Rabinowitz
    Chief Commercial Officer
  • Estee Yaari
    Investor Relations Contact













ORMP Stock - Frequently Asked Questions

Should I buy or sell Oramed Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares.
View ORMP analyst ratings
or view top-rated stocks.

What is Oramed Pharmaceuticals' stock price forecast for 2023?

3 brokers have issued 1-year target prices for Oramed Pharmaceuticals' stock. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they expect the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 779.6% from the stock's current price.
View analysts price targets for ORMP
or view top-rated stocks among Wall Street analysts.

How have ORMP shares performed in 2023?

Oramed Pharmaceuticals' stock was trading at $12.03 at the beginning of 2023. Since then, ORMP shares have decreased by 82.0% and is now trading at $2.16.
View the best growth stocks for 2023 here
.

When is Oramed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our ORMP earnings forecast
.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 1,353.35% and a negative trailing twelve-month return on equity of 23.62%.

What ETFs hold Oramed Pharmaceuticals' stock?

ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Millennium Management LLC (1.25%), JPMorgan Chase & Co. (1.03%), Lindbrook Capital LLC (0.98%), Morgan Stanley (0.81%), Susquehanna International Group LLP (0.00%) and Citigroup Inc. (0.17%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov.
View institutional ownership trends
.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $2.16.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $85.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.

This page (NASDAQ:ORMP) was last updated on 3/22/2023 by MarketBeat.com Staff